2型糖尿病应用罗格列酮前后CRP WBC变化

Changes in C-Reactive Protein White Blood Cells Counts in Patients with Type 2 Diabetes Mellitus Before and After Treatment with Rosiglitazone

目的观察应用罗格列酮对2型糖尿病(T2DM)患者体内C反应蛋白(CRP)及白细胞(WBC)水平的影响。方法89例已合用磺脲类和双胍类药物的T2DM患者采用随机、双盲、安慰剂、平行对照方法分至罗格列酮组及安慰剂组,进行3个月的临床观察,治疗前及治疗3个月后分别检测空腹血糖(FPG)、餐后2h血糖(2hPG)、糖化血红蛋白(HbA1 c)、胆固醇(TC)、甘油三脂(TG)、低密度脂蛋白(LDL-C)、高密度脂蛋白(HDL-C)、血胰岛素(FIns)、C反应蛋白(CRP)、白细胞计数(WBC),比较各指标的变化,另外选择同期检查的健康志愿者44例作为健康对照组。结果罗格列酮治疗3个月后患者的CRP、WBC出现显著下降(P<0.01),FPG、2hPG、HbA1 c、TG、HOMA-IR亦显著下降(P<0.05),HDL-C则明显上升(P<0.05)。结论T2DM患者应用罗格列酮治疗,不仅可以改善其糖脂代谢,还可降低患者体内部分炎症因子的水平,可能对2型糖尿病患者预防慢性并发症有益。

Objective To observe the changes in serum C -reactive protein （CRP） and white blood cells （WBC） counts in patients with type 2 diabetes mellitus after treatment with rosiglitazone. Methods A 3 - month randomized, double - blind placebo controlled study was performed to compare the effect of placebo and rosiglitazone 4mg/d in 89 type 2 diabetic patients who had received sulfonylureas and metformin treatment. Some markers such as fasting plasma glucose （ FPG）, 2h plasma glucose （2hPG）, glycosylated hemoglobin （nbAlc）, cholesterol （TC）, triglyceride （TG）, low - density lipoprotein cholesterol （ LDL - C ）, high - density lipoprotein cholesterol （ HDL - C ）, fast insulin（ Fins）, C - reactive protein （ CRP）, white blood cells （WBC） counts were measured before and after treatment. In addition, result of simultaneous examination over 44 healthy volunteers was chosen as contrast. Results A significant reduction in CRP, WBC level was observed after 3 - month treatment with rosiglitazone （ P 〈0.01 ）. So were FPG, 2hPG, HbAlc, TG, and HOMA-IR（ P 〈 0.05 ）. But there was a significant increase in HDL - C （ P 〈 0. 05 ）. Conclusion The use of rosiglitazone in patients with T2DM can not only improve their glucose, blood - lipid metabolism but also decrease the level of some inflammatory makers, and may have possible good effect to preventing complications of the patients with T2DM.